Even for cancer types other than ovarian cancer, the difference in PFS with bevacizumab is often greatest around 12 months.2 The main action of bevacizumab, an anti-VEGF-A antibody, is inhibition of angiogenesis in tumor tissue. Here, VEGFA is linked to cancer.